AtriCure (NASDAQ:ATRC) Upgraded by Zacks Research to Strong-Buy Rating

Zacks Research upgraded shares of AtriCure (NASDAQ:ATRC) from a hold rating to a strong-buy rating in a research note published on Wednesday morning,Zacks.com reports.

ATRC has been the subject of several other reports. Canaccord Genuity Group increased their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $45.00 price target on shares of AtriCure in a research note on Thursday, February 12th. Freedom Capital raised shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. BTIG Research reiterated a “buy” rating and set a $54.00 price objective on shares of AtriCure in a research note on Wednesday, February 18th. Finally, Weiss Ratings lowered shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.71.

AtriCure Stock Down 0.7%

Shares of ATRC stock opened at $27.80 on Wednesday. The stock’s fifty day moving average price is $29.24 and its 200 day moving average price is $34.28. AtriCure has a 1-year low of $26.62 and a 1-year high of $43.18. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -278.00 and a beta of 1.28. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.96 and a quick ratio of 2.99.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, May 5th. The medical device company reported $0.00 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The company had revenue of $141.25 million during the quarter, compared to analysts’ expectations of $139.75 million. During the same period last year, the business posted ($0.14) earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. On average, research analysts expect that AtriCure will post 0.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AtriCure news, insider Vinayak Doraiswamy sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $29.83, for a total transaction of $149,150.00. Following the completion of the transaction, the insider directly owned 96,875 shares of the company’s stock, valued at approximately $2,889,781.25. This trade represents a 4.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ATRC. Marshall Wace LLP lifted its position in AtriCure by 63.4% during the fourth quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock valued at $36,136,000 after purchasing an additional 354,281 shares during the period. Wellington Management Group LLP raised its stake in shares of AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after buying an additional 322,818 shares during the last quarter. First Light Asset Management LLC lifted its holdings in shares of AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock valued at $46,501,000 after buying an additional 285,083 shares during the period. Kennedy Capital Management LLC lifted its holdings in shares of AtriCure by 36.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 836,916 shares of the medical device company’s stock valued at $29,501,000 after buying an additional 222,529 shares during the period. Finally, Norges Bank purchased a new stake in shares of AtriCure in the fourth quarter worth about $8,466,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.